DAFTAR PUSTAKA

DAFTAR PUSTAKA

American Cancer Society. Cancer Facts & Figures. 2014. Arthur RR, Shah KV, Charache P, Saral R. BK and JC virus infections in recipients of bone

marrow transplants . J Infect Dis 1988;158:563-569. Auberger J, Lass-Florl C, Ulmer H, et al. Significant alterations in the epidemiology and

treatment outcome of invasive fungal infections in patients with hematological malignancies . Int J Hematol 2008;88:508-15.

Beck JC, Wagner JE, DeFor TE, et al. Impact of cytomegalovirus (CMV) reactivation after umbilical cord transplantation . Biol Blood Marrow Transplant 2010;16:215-22.

Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients . Blood 2009;113:5711-9.

Bollee G, Sarfati C, Thiery G, et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients . Chest 2007;132:1305-10.

Bowers DR, Liew YX, Lye DC, et al. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia . Antimicrob Agents Chemother 2013;57:1270-4.

Brusch JL, Weinstein L. Fever of unknown origin . Med Clin North Am 1988;72:1247-61. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in

patients with cancer and neutropenia . N Engl J Med 2005;353:977-87. Centers for Disease Control and Prevention. Preventing Infections in Cancer Patients.

2014. Centers for Disease Control and Prevention. Seasonal Influenza. 2014. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole

prophylaxis in patients with neutropenia . N Engl J Med 2007;356:348-359. Dolton MJ, Ray JE, Chen SC, et al. Multicenter study of posaconazole therapeutic drug

monitoring: exposure-response relationship and factors affecting concentration . Antimicrob Agents Chemother 2012;56:5503-10

Fausel CA. Neutropenia and agranulocytosis. In: Tisdale JE, Miller DA, eds. Drug-induced Diseases: Prevention, Detection,and Management. 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists; 2010: 962-971.

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America . Clin Infect Dis 2011;52:e56-e93.

Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy . Cochrane Database Syst Rev 2012 Jan 18;1:CD004386.

George B, Pati N, Gilroy N, et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy . Transpl Infect Dis 2010;12:322-9.

Hu Y, Li L, Li W, et al. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies . Int J Antimicrob Agents 2013;42:492-6.

Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study . Blood 2002;99:3554-61.

Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a doubleblind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/ clavulanic acid combination therapy--EORTC infectious diseases group trial XV . J Clin Oncol 2013;31:1149-56.

Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients . J Clin Oncol 2000;18:3038-51.

Klastersky J . Management of fever in neutropenic patients with different risks of complications . Clin Infect Dis 2004;39 Suppl 1:S32-7.

Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients . Int J Antimicrob Agents 2007;30 Suppl 1:S51-9.

Knowles W. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV) . Adv Exp Med Biol 2006;577:19-45.

Koh LP, Kurup A, Goh YT, et al. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation . Am J Hematol 2002;71:260-7.

Kuderer NM, Dale DC, Crawford J, Cosler LE, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer 2006;106:2258-

66. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte

colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review . J Clin Oncol 2007;25:3158-67.

Limper AH, Offord KP, Smith TF, Martin WJ. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS . Am Rev Respir Dis 1989;140:1204.

Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors . Blood 2002;100:4358-

66. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of

fungal infections in patients receiving allogeneic stem cell transplants . Blood 2004;103:1527-1533.

Marr KA, Seidel L, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial . Blood 2000;96:2055-2061.

Martin-Garrido I, Carmona EM, Specks U, et al. Pneumocystis pneumonia in patients treated with rituximab . Chest 2013;144:258-65.

Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell- mediated immunity after marrow transplant . J Infect Dis 1980;142:338-346.

National Cancer Institute. Nutrition and cancer care (PDQ) . 2011. National Institutes of Health (NIH). Lymphocytopenia . 2013. National Institutes of Health (NIH). Pets and the Immunocompromised Person . 2014. Nguyen TD, Williams B, Trang E. Cefepime therapy all-cause mortality . Clin Infect Dis

2009;49:902-4. Patel RA, Gallagher JC. Drug Fever . Pharmacotherapy 2010;30:57-69. Paul M, Borok S, Fraser A, et al. Empirical antibiotics against gram-positive infections for

febrile neutropenia: systematic review and meta-analysis of randomized controlled trials . J Antimicrob Chemother 2005;55:436-44.

Pietersma FL, van Dorp S, Minnema MC, et al. Influence of donor on cytomegalovirus (CMV) status on severity of viral reactivation after allogeneic stem cell transplantation in CMVseropositive recipients . Clin Infect Dis 2011;52:e144-48.

Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial . Clin Infect Dis 2008;46:1401-1408.

Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients . Am J Med 1986;80:13-20.

Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double- blind study . J Infect Dis 1995;171:1545-52.

Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection . Ann Intern Med 2007;147:400-11.

Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study . J Clin Oncol 2005;23:7974-84.

Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gramnegative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact . Curr Opin Infect Dis 2014;27:200-10.

U.S. Food and Drug Administration (FDA). Information for Healthcare Professionals: Cefepime .2009.

U.S. Food and Drug Administration (FDA). Food Safety for People with Cancer . 2014. van Burik J-AH, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for

prophylaxis against invasive fungal infections during neutropenia in patients undergoing

hematopoietic stem cell transplantation . Clin Infect Dis 2004;39:1407-1416. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of

pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study . J Clin Oncol 2005;23:1178-84.

von Baum H, Sigge A, Bommer M, et al. Moxifloxacin prophylaxis in neutropenic patients . J Antimicrob Chemother 2006;58:891-4.

Vardakas KZ, Tansarli GS, Bliziotis IA, et al. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis . Int J Antimicrob Agents 2013;41:301-10.

Wald A, Leisenring W, van Burik JA, et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation . J Infect Dis 1997;175:1459-66.

Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever . N Engl J Med 2002;346:225-34.

Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia .N Engl J Med 2004;351:1391-402.

Wingard JR, Carter SL, Walsh TJ, et al. Randomized, doubleblind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation . Blood 2010;116:5111-8.

Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis . Lancet Infect Dis 2007;7:338-48.

Zaia J, Baden L, Boeckh MJ, et al. Viral disease prevention after hematopoietic cell transplantation . Bone Marrow Transplant 2009;44:471-82.